

# Maria Alice V Willrich

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6854358/publications.pdf>

Version: 2024-02-01

44  
papers

684  
citations

471509  
17  
h-index

580821  
25  
g-index

44  
all docs

44  
docs citations

44  
times ranked

998  
citing authors

#	ARTICLE	IF	CITATIONS
1	Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clinic Proceedings, 2016, 91, 1189-1211.	3.0	55
2	CYP3A5*3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. Clinica Chimica Acta, 2008, 398, 15-20.	1.1	54
3	Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC-MS/MS. International Immunopharmacology, 2015, 28, 513-520.	3.8	52
4	Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response. International Journal of Molecular Sciences, 2011, 12, 5815-5827.	4.1	49
5	CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1071-1080.	2.3	45
6	Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Clinical Biochemistry, 2018, 51, 38-47.	1.9	43
7	Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 580-586.	1.9	40
8	Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1085-93.	2.3	37
9	Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Advances in Clinical Chemistry, 2016, 77, 1-75.	3.7	36
10	The Complement Alternative Pathway and Preeclampsia. Current Hypertension Reports, 2018, 20, 40.	3.5	34
11	A High-Level Overview of the Regulations Surrounding a Clinical Laboratory and Upcoming Regulatory Challenges for Laboratory Developed Tests. Laboratory Medicine, 2021, 52, 315-328.	1.2	25
12	Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. Analytical Chemistry, 2016, 88, 6317-6325.	6.5	24
13	The impact of eculizumab on routine complement assays. Journal of Immunological Methods, 2018, 460, 63-71.	1.4	22
14	Effects of ABCA1 SNPs, including the C-105T novel variant, on serum lipids of Brazilian individuals. Clinica Chimica Acta, 2008, 389, 79-86.	1.1	21
15	Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholesterolemic patients. Clinica Chimica Acta, 2013, 421, 157-163.	1.1	20
16	Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome. Mayo Clinic Proceedings, 2018, 93, 1351-1362.	3.0	17
17	CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis. Mayo Clinic Proceedings, 2022, 97, 738-751.	3.0	17
18	Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease. American Journal of Hematology, 2020, 95, E222-E225.	4.1	15

#	ARTICLE	IF	CITATIONS
19	Genetic variation in statin intolerance and a possible protective role for <i>UGT1A1</i> . <i>Pharmacogenomics</i> , 2018, 19, 83-94.	1.3	10
20	Monitoring Ravulizumab effect on complement assays. <i>Journal of Immunological Methods</i> , 2021, 490, 112944.	1.4	9
21	Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3548-3554.	2.3	8
22	Comparison of Clinical Laboratory Assays for Measuring Serum Infliximab and Antibodies to Infliximab. <i>Journal of Applied Laboratory Medicine</i> , 2018, 2, 893-903.	1.3	6
23	Assessment of complement interference in anti-M $\beta$ 1/4llerian hormone immunoassays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 58, e8-e10.	2.3	4
24	Limited Significance of Antifactor H Antibodies in Patients with Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 939-941.	4.5	4
25	Complement testing in the clinical laboratory. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 447-478.	6.1	4
26	MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins. <i>Clinical Biochemistry</i> , 2021, 97, 67-73.	1.9	4
27	PCSK9 and the Road Less Traveled: How an Unconventional Approach Led to a Major Discovery. <i>Clinical Chemistry</i> , 2013, 59, 1283-1284.	3.2	3
28	Analysis of Tryptic Peptides from Therapeutic Monoclonal Antibodies Using LC-MS/MS. <i>Methods in Molecular Biology</i> , 2019, 1872, 85-99.	0.9	3
29	Limitations of Free Light Chain Assays caused by the Matrix Effect. <i>Journal of Applied Laboratory Medicine</i> , 2020, 5, 311-319.	1.3	3
30	Novel Genetic Variants in Complement-Mediated Thrombotic Microangiopathy. <i>Blood</i> , 2015, 126, 1050-1050.	1.4	3
31	Performance of perpendicular drop versus tangent skimming gating of M-protein in proficiency testing challenges. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e19-e22.	2.3	3
32	Therapeutic Monoclonal Antibodies in the Clinical Laboratory. <i>Journal of Applied Laboratory Medicine</i> , 2017, 2, 454-457.	1.3	2
33	Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease. <i>Crohn's &amp; Colitis</i> 360, 2019, 1, .	1.1	2
34	Liquid Chromatography-Tandem Mass Spectrometry-Based $\pm$ 1-Antitrypsin (AAT) Testing. <i>American Journal of Clinical Pathology</i> , 2021, 155, 547-552.	0.7	2
35	Quantitative Alterations in Complement Alternative Pathway and Related Genetic Analysis in Severe Phenotype Preeclampsia. <i>Kidney</i> 360, 2021, 2, 1463-1472.	2.1	2
36	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020, 136, 48-49.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. <i>Crohn's &amp; Colitis</i> 360, 2021, 3, .	1.1	1
38	A Case of Unexpected Hyperglycemia. <i>Clinical Chemistry</i> , 2021, 67, 1056-1059.	3.2	1
39	Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease. <i>Blood</i> , 2019, 134, 3510-3510.	1.4	1
40	Determination of Relapse Risk By Complement Gene Variants after Eculizumab Discontinuation in Complement-Mediated Thrombotic Microangiopathy: A Retrospective Review. <i>Blood</i> , 2020, 136, 25-26.	1.4	1
41	Correlation Between Kappa Prozone Effect and IgA Kappa M Proteins in Serum Free Light-Chain Assay. <i>Clinical Chemistry</i> , 2019, 65, 1327-1329.	3.2	0
42	A Rapid MALDI-TOF Method for Isotyping and Quantitating M-Proteins in a Single Assay: Longitudinal Comparison to Serum Protein Electrophoresis and Hevylite for Monitoring Patients with Monoclonal Gammopathies. <i>Blood</i> , 2015, 126, 1780-1780.	1.4	0
43	Commentary on Significance of Monoclonal Band in Cerebral Spinal Fluid. <i>Clinical Chemistry</i> , 2022, 68, 281-281.	3.2	0
44	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. <i>Blood</i> , 2020, 136, 44-45.	1.4	0